Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shortened infusion times for monoclonal antibody therapies
NL-OMON59313Phase 4Recruiting
- Sponsor
- Isala
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of trastuzumab, nivolumab, pembrolizumab, ipilimumab, bevacizumab and 3 more in cancer, inflammatory bowel disease (IBD) and rheumatism (2 cohorts), sponsored by Isala. Primary endpoints: Number of infusion-related reactions and Grade of infusion-related reactions. Started Nov 2024; status: recruiting.
02
Drugs
03
Conditions
cancerinflammatory bowel disease (IBD)rheumatism
Beyond the preview
Go deeper on NL-OMON59313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59313.